Hepatitis A Vaccine Market Growth and Key Drivers
The hepatitis A vaccine market, valued at $742.31 million in 2023, is projected to reach $948.16 million by 2034, growing at a CAGR of 2.25%. Rising outbreaks, increased immunization awareness, and expanding travel are fueling this steady growth.
Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5301
Hepatitis A Vaccine Market Strengthening Global Immunity
The hepatitis A vaccine is a critical tool in preventing hepatitis A, a liver infection caused by the hepatitis A virus. It is recommended for children aged 12-23 months as part of routine immunizations. The CDC also advises vaccination for people with chronic liver disease, those who use clotting factor concentrates, individuals in close contact with the virus, and communities experiencing outbreaks. The vaccine offers long-lasting protection, effective for at least 20 years, and possibly a lifetime.
With rising hepatitis A outbreaks and increasing rates of HIV and chronic liver disease, the demand for vaccines continues to grow. According to the WHO, around 354 million people worldwide are affected by hepatitis A, contributing to 1.3 million deaths annually. Supportive government policies and WHO-backed immunization guidelines are also driving the market forward.
Emerging Trends in the Hepatitis A Vaccine Market
Sanofi introduced Avaxim Junior, an inactivated hepatitis A vaccine for children aged 12 months to 15 years, in the UK in April 2023. Clinical trials across 14 countries showed the vaccine provided protection within two weeks for more than 95% of individuals.
Meanwhile, GlaxoSmithKline plc reported strong growth in 2023-24, with total sales of £30.3 billion. Vaccine sales surged by 25%, contributing to an operating profit of £6.7 billion, underscoring the rising demand for immunization solutions globally.
Top Companies in the Hepatitis A Vaccine Market
- Changchun Institute of Biological Products
- GlaxoSmithKline plc
- Indian Immunologicals Limited
- Instituto Butantan
- Janssen Vaccines
- Johnson & Johnson
- KM Biologics
- Merck & Co., Inc.
- Moderna, Inc.
- Sanofi Pasteur S.A.
- Sinopharm
- Sinovac Biotech Ltd.
- Zerun Biotech
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/hepatitis-a-vaccine-market-sizing
Access exclusive insight now @ https://www.towardshealthcare.com/price/5301
We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com
Web: https://www.towardshealthcare.com
Visit Dental Specifics: https://www.towardsdental.com
Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription
For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
